Literature DB >> 26158622

Optimal vaccination program for healthy adults in China.

Jun Yao1, Yan Qiu2, Yongdi Chen1, Zhenggang Jiang1, Lingzhi Shen1, Huan Shan3, Xuewei Dai4, Qian Li1, Ying Liu2, Wen Ren2, Jingjing Ren2.   

Abstract

There is still no suitable routine hepatitis B immunization strategy for adults in China. To establish an optimal vaccination schedule for healthy adults, we investigated various schedules in healthy adults. In this randomized 5143 healthy adults received 10 μg hepatitis B vaccine at 0, 1 and 3 months(group A), 0, 1 and 6 months(group B), or 0, 1 and 12 months(group C). Blood samples were collected after 1 month and 12 months after the third dose. The geometric mean titer (GMT), seroconversion rate (levels of anti-HBs ≥ 10 mIU/mL) and high response rate (levels of anti-HBs ≥ 100 mIU/mL) were assayed. In our study, 2438 healthy adults finished the full vaccination program and follow-up. The seroconversion/sero-protective rate of groups A-C at one and 12 month after administration of the third vaccine dose was 100%, 99.9% and 97.9% verse 64.9%, 75.7% and 79.0%, respectively. GMT for anti-HBs tested in group A to C within 1 or 12 month after the third vaccination was 213.16, 432.58 and 451.47 mIU/ml verse 22.07, 46.70 and 56.18 mIU/ml, respectively. There were significant differences of seroconversion/sero-protective rate and GMT among the 3 groups (p < 0.01). Given the high anti-HBs seroconversion rate and GMT in all 3 groups, a flexible schedule for Hepatitis B vaccine should be recommended to adults, but 0-1-12 schedule is a better choice.

Entities:  

Keywords:  adult vaccination; anti-HBs titers; hepatitis B vaccine; immunogenicity

Mesh:

Substances:

Year:  2015        PMID: 26158622      PMCID: PMC4635859          DOI: 10.1080/21645515.2015.1053674

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  20 in total

1.  Effect of timing of hepatitis B vaccine doses on response to vaccine in Yucpa Indians.

Authors:  S C Hadler; M A de Monzon; D R Lugo; M Perez
Journal:  Vaccine       Date:  1989-04       Impact factor: 3.641

2.  Immunological effects of a 10-μg dose of domestic hepatitis B vaccine in adults.

Authors:  Jing-jing Ren; Xue-wei Dai; Zheng-gang Jiang; Ling-zhi Shen; Yong-di Chen; Qian Li; Wen Ren; Ying Liu; Jun Yao; Lan-juan Li
Journal:  J Zhejiang Univ Sci B       Date:  2012-11       Impact factor: 3.066

3.  Obesity as a predictor of poor antibody response to hepatitis B plasma vaccine.

Authors:  D J Weber; W A Rutala; G P Samsa; J E Santimaw; S M Lemon
Journal:  JAMA       Date:  1985-12-13       Impact factor: 56.272

4.  Immunogenicity of standard and low dose vaccination using yeast-derived recombinant hepatitis B surface antigen in elderly volunteers.

Authors:  S de Rave; R A Heijtink; M Bakker-Bendik; J Boot; S W Schalm
Journal:  Vaccine       Date:  1994-05       Impact factor: 3.641

5.  Antibody levels and protection after hepatitis B vaccination: results of a 15-year follow-up.

Authors:  Brian J McMahon; Dana L Bruden; Kenneth M Petersen; Lisa R Bulkow; Alan J Parkinson; Omana Nainan; Marina Khristova; Carolyn Zanis; Helen Peters; Harold S Margolis
Journal:  Ann Intern Med       Date:  2005-03-01       Impact factor: 25.391

6.  Effect of anatomic injection site, age and smoking on the immune response to hepatitis B vaccination.

Authors:  F E Shaw; H A Guess; J M Roets; F E Mohr; P J Coleman; E J Mandel; R R Roehm; W S Talley; S C Hadler
Journal:  Vaccine       Date:  1989-10       Impact factor: 3.641

7.  Vaccination against hepatitis B: comparison of three different vaccination schedules.

Authors:  W Jilg; M Schmidt; F Deinhardt
Journal:  J Infect Dis       Date:  1989-11       Impact factor: 5.226

8.  Overview of a 5-year clinical experience with a yeast-derived hepatitis B vaccine.

Authors:  F E André
Journal:  Vaccine       Date:  1990-03       Impact factor: 3.641

9.  Immunogenicity of hepatitis B Vaccines. Implications for persons at occupational risk of hepatitis B virus infection.

Authors:  F Averhoff; F Mahoney; P Coleman; G Schatz; E Hurwitz; H Margolis
Journal:  Am J Prev Med       Date:  1998-07       Impact factor: 5.043

10.  A controlled clinical trial of the efficacy of the hepatitis B vaccine (Heptavax B): a final report.

Authors:  W Szmuness; C E Stevens; E A Zang; E J Harley; A Kellner
Journal:  Hepatology       Date:  1981 Sep-Oct       Impact factor: 17.425

View more
  2 in total

1.  Factors influencing immunologic response to hepatitis B vaccine in adults.

Authors:  Shigui Yang; Guo Tian; Yuanxia Cui; Cheng Ding; Min Deng; Chengbo Yu; Kaijin Xu; Jingjing Ren; Jun Yao; Yiping Li; Qing Cao; Ping Chen; Tiansheng Xie; Chencheng Wang; Bing Wang; Chen Mao; Bing Ruan; Tian'an Jiang; Lanjuan Li
Journal:  Sci Rep       Date:  2016-06-21       Impact factor: 4.379

2.  Timing of primary three-dose hepatitis B vaccination and postvaccination serologic testing among a large cohort of healthy adults.

Authors:  Özgür M Koc; Eva van Oorschot; Lloyd Brandts; Astrid Oude Lashof
Journal:  J Med Virol       Date:  2022-05-17       Impact factor: 20.693

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.